Irinotecan

SKU: orb1300959

Description

Irinotecan

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 97682-44-5
• MW: 586.68
• Purity: 99.92%
• Formula: C₃₃H₃₈N₄O₆
• SMILES: CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12
• Target: Autophagy,Topoisomerase
• Solubility: DMSO:11 mg/mL (18.75 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.2 mg/mL (5.45 mM)

Bioactivity

• Target IC50:
  SW480 cells viability:1.4 μM (2 h,MTT assay)|A375 cells viability:4 nM|K562 cells proliferation:1.9 μM (GI50,72h)|CCD-841CoN cells proliferation:13.2 μM (72h,SRB assay) A549 cells proliferation:0.8 μM (2 h,MTS assay) A549 cells proliferation:20 μM (72h,MTT assay)|HepG2 cells proliferation:5.94 μM (GI50,72h,XTT assay)|A431 cells proliferation:4.1 μM|Hep 3B2 cells proliferation:4.73 μM (GI50,72h,XTT assay)|786-O cells viability:2.25 μM|Mouse bone marrow cells viability:1 nM|HCT15 cells proliferation:8.5 μM|A2780 cells proliferation:3.8 μM|HT29 cells proliferation:3.96 μM (2 h,MTT assay)|HT29 cells proliferation:9.5 μM (72h,SRB assay)
• In Vivo:
  METHODS: To tes the antitumor activity in vivo Irinotecan (40 mg/kg) was administered intraperitoneally three times a week for four weeks to an NSG mouse model of MLL rearrangement All xenografts. Results: Irinotecan effectively inhibite the growth of MLL rearrangement All in vivo METHODS: To assay anti-tumor activity in vivo Irinotecan (10 mg/kg four times every four days or 40 mg/kg Six times every four days) was administered intraperitoneally to swiss nu/nu mice bearing five CRC xenograft tumors. Results: At low doses of Irinotecan, four o the five xenografts responded to Irinotecan with a growth delay of up to 10 days. At high doses of Irinotecan, five xenografts showed variable but significant responses.
• In Vitro:
  METHODS: Human breast cancer cells MCF-7 were treated with Irinotecan (10-320 µg/mL) for 24-48 h. Cell viability was measured by trypan blue. Results: Cell viability decreased to 85.5% at 10 µg mL and 58% at 160 µg mL with Irinotecan treatment for 24 h. Viability decreased to 33% at 160 µg mL with Irinotecan treatment for 48 h. METHODS: HCT116 p53-/-,hMLH1+, p53-/-,hMLH1- and p53-/-,hMLH1- were treated with Irinotecan (4.5 µM) for 48 h. Cell cycle profiles were analyzed by Flow Cytometry. Results: Irinotecan treatment induced G2/M arrest of different durations in All three cell lines the block was maintained for at least 12 days in the p53-/-, hMLH1+ cell lines the slow release o the block in the p53-/-, hMLH1- cell line 6-9 days after treatment initiation suggests tha the status o the hMLH1 molecule may indirectly or directly influenc the maintenance of G2/M block. in the p53-/- cell line, G2/M block was terminated within 4 days of treatment initiation.
• Cell Research:
  Irinotecan is dissolved in DMSO and stored, and then diluted with appropriate medium before us. To determin the effects of Irinotecan in combination with 5-FU the MTT assay is used. Depending o the cell lines, 10,000 to 20,000 cells per well are seeded in 96-well plates and incubated for 24 h in complete medium. On day 2, cells are incubated in the absence or presence of Irinotecan for 30 min followed by 5-FU for 24 h. After a Other 24 h in complete medium without any additives, MTT reagent is added on day 4 to initiat the assay an the cells are incubated for an additional 4 h at 37℃. After removal o the medium and dissolvin the crystals with acidified isopropanol the Samples are analyzed using an ELISA plate reader at 570 nM the value at 650 nM is subtracted as backgroun.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

inhibit, Inhibitor, Irinotecan, CPT 11, CPT11, CPT-11, Autophagy, (+)-Irinotecan, Topoisomerase, Topo I, Topotecin

Compound Identifiers

PubChem CID

60838